Bortezomib in Treating Patients With Unresectable or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

NCT00074009 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

OTHER

Sponsor class

Conditions

Gastric Cancer

Interventions

DRUG: bortezomib

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]